ClinicalTrials.gg
RecruitingNCT07495241CaWYUpdated Mar 27, 2026

Prevalence of Carotid Web in Youth

An observational study in Carotid Web, sponsored by University of Ostrava. Recruiting at 1 site in Czechia. Open to participants aged 15 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by University of Ostrava · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
829
Ages
15 Years to 25 Years
Sex
All
01

Study summary

A carotid web (CaW) is a shelf-like, thin, triangular endoluminal projection typically arising from the posterior wall of the internal carotid artery (ICA) bulb. CaW is considered by many to be an intimal variant of fibromuscular dysplasia and is associated with an increased risk of ischemic stroke in otherwise low-risk, younger patients. The CaWY study is a cross-sectional, multicenter, population-based sonographic survey with blinded central image adjudication, reported in accordance with STROBE guidelines for cross-sectional studies, aimed at estimating the prevalence of CaW detected by duplex sonography in the general population aged 15-25 years.

Read the detailed description
  1. Background and Rationale A carotid web (CaW) is a shelf-like, thin, triangular endoluminal projection-typically arising from the posterior wall of the internal carotid artery (ICA) bulb-considered by many to be an intimal variant of fibromuscular dysplasia and associated with embolic ischemic stroke in otherwise low-risk, younger patients. Although CT angiography (CTA) is most frequently used to diagnose CaW, characteristic appearances are detectable on longitudinal B-mode carotid duplex ultrasound (DUS) with supportive Doppler findings; microflow/superb microvascular imaging can improve conspicuity. Population prevalence in the general young adult population is unknown; most estimates come from stroke cohorts (≈2% among symptomatic populations; higher within cryptogenic stroke subsets), so a dedicated, population-based sonographic study is needed.
  2. Objectives and Hypotheses Primary objective: Estimate the point prevalence of carotid web in a general young adult population aged 15-25 years using duplex sonography.

    Secondary objectives:

    • Describe CaW laterality and morphology (web thickness, length, and projection angle) on ultrasound.
    • Estimate prevalence of concomitant ICA/common carotid artery (CCA) atherosclerotic changes or stenosis.
    • Assess inter-observer agreement for CaW detection on DUS.
    • In an adjudicated subset, compare DUS-suspected CaW with CTA (optional validation).

    Hypothesis: Carotid web is present in 2 % of the general 15-25-year population (two-sided). (This is a planning assumption; true prevalence may be lower/higher. Literature in symptomatic cohorts ranges roughly 2%, higher in cryptogenic stroke; general-population data are lacking.)

  3. Study Design Cross-sectional, multicenter, population-based sonographic survey with blinded central image adjudication, reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for cross-sectional studies.
  4. Study Population Setting \& sampling frame

    • Community-based recruitment (secondary schools/universities).
    • Stratified cluster sampling by sex, age bands (15-17, 18-21, 22-25), and recruitment site to approximate the underlying population.
  5. Sample Size Assumptions

    • Expected prevalence p=0.02 (2%)
    • Desired absolute precision d=0.01 (±1%)
    • Confidence level 95% → Z=1.96 Formula n = Z2 p(1-p)d2 = 1.962×0.02×0.980.012 = 752.95n \;=\; \frac{Z\^2\, p(1-p)}{d\^2} \;=\; \frac{1.96\^2 \times 0.02 \times 0.98}{0.01\^2} \;=\; 752.95n=d2Z2p(1-p)=0.0121.962×0.02×0.98=752.95 Required minimum sample size: 753 participants (round up) plus 10% for non-diagnostic/poor-quality scans and no-shows, i.e. totally 829 participants is needed to screen.
  6. Ultrasound Acquisition Protocol Equipment \& presets

    • High-end ultrasound suplex machine Canon Aplio a-series with B-mode, color/power Doppler, spectral Doppler, and microflow/superb microvascular imaging. High-frequency linear transducer PLT-1005BT (5-14 MHz).
    • Patient supine, slight neck extension/contralateral head rotation; optimize for the carotid bulb/ICA origin.

Scanning sequence (bilateral)

  1. B-mode: transverse sweep from distal CCA through bulb into proximal ICA and extracranial carotid artery (ECA); then longitudinal (anterolateral, lateral, posterolateral windows).
  2. Color Doppler: at low pulse repetition frequency (PRF) to visualize flow separation/recirculation; adjust wall filter and gain to avoid overwriting thin intraluminal structures.
  3. Spectral Doppler: with angle correction ≤60°, use a sample volume of 1.5-2.0 mm; measure peak systolic velocity (PSV) and end-diastolic velocity (EDV) in standard segments (distal CCA, bulb, proximal ICA).
  4. Microflow imaging: focused on the posterolateral bulb to delineate the thin shelf/membrane and adjacent flow.

Image storage

  • Mandatory cine loops (≥3 cardiac cycles) in longitudinal and transverse views of the bulb/ICA origin, plus still frames with and without color, and spectral Doppler waveforms with angle annotation (same as in protocol of ANTIQUE study - ClinicalTrials.gov ID NCT02360137).
  • Label side and projection; record machine make/model, probe, presets. 7) Sonographic Definition of Carotid Web

Definite carotid web:

Inclusion criteria:

  1. Focal echogenic lesion in the carotid bifurcation (15 mm proximally to the flow divider and 15 mm distally)
  2. The lesion is present (interferes) in the posterior wall
  3. Echogenicity of the lesion is higher than that of intraluminal blood
  4. Maximal length of lesions 3.0 mm
  5. Minimal intraluminal prominence (width) 2.0 mm
  6. In longitudinal view: The shape of the lesion is shelf-like or valve-like, triangular with the sharpest angle proximally, with the blood flow direction
  7. In transversal view: Transversal linear defect with echogenic surface projecting in the arterial lumen (the shape should be nest-like)
  8. Hemodynamic signature: focal flow separation/recirculation or color aliasing immediately distal to the shelf without proportionate atherosclerotic plaque; spectral Doppler may be normal or show subtle focal acceleration without classic stenosis criteria.

Exclusion criteria:

  1. The length is greater than the width
  2. Visible only in transversal and not longitudinal view
  3. Presence of carotid plaque (Mannheim consensus) in the posterior wall

Suspected carotid web:

Inclusion criteria:

1. Focal echogenic lesion in the carotid bifurcation (15 mm proximally to the flow divider and 15 mm distally) 2. Minimal intraluminal prominence (width) 1.5 mm 3. One out of these criteria:

  1. In longitudinal view: Shape of lesion is shelf-like or valve-like, triangular with the sharpest angle proximally, with the blood flow direction
  2. In transversal view: Transversal linear defect with echogenic surface projecting in the arterial lumen (the shape should be nest-like)

    Exclusion criteria:

    1. Presence of carotid plaque (Mannheim consensus) in the posterior wall

    Differential sonographic features to record: typical plaque (echogenic/heterogeneous with surface calcification), carotid diaphragm, dissection flap (mobile, intramural hematoma), carotid web with superimposed thrombus.

    7) Sonographic Case Definition of Carotid Web

    Required equipment/settings (if specified in your criteria):

    • Probe/frequency: 5-14 MHz
    • Settings: mechanical index of 1.6, 37 fps, Q scan, dynamic range 70
    • Patient position: supine position, slight neck extension/contralateral head rotation

    Diagnostic categories (tick all that apply):

    • Definite CaW - must meet morphology, location, hemodynamics criteria, and exclusions ruled out (plaque, dissection, diaphragm, artifact).
    • Probable CaW - meets some morphology criteria and exclusions ruled out (plaque, dissection, diaphragm, artifact).
    • Not CaW - meets no criteria for CaW.

    Morphologic measurements (standardized):

    • Web thickness (mm): ____ (measured at ______)
    • Web length/projection into lumen (mm): ____
    • Projection angle (°) relative to vessel wall: ____
    • Distance from flow divider (mm): ____
    • Side: left / right / bilateral

    Hemodynamic signatures (as per your thresholds):

    • Color Doppler recirculation/aliasing: present / absent (criteria: ______)
    • Spectral Doppler acceleration: PSV ___ m/s (cutoff: ___); ICA/CCA ratio cutoff: ___
    • Microflow imaging pattern: ______

    Differential exclusion checklist (define image features to rule out):

    • Atherosclerotic plaque: ______
    • Dissection flap/intramural hematoma: ______
    • Carotid diaphragm/other membranes: ______
    • Artifact (reverberation, blooming): ______

    Image acquisition minimums (per side):

    • Transverse cine (≥3 cycles) focused on bulb/ICA origin
    • Longitudinal cine in ≥2 insonation planes (lat \& post-lat)
    • Still frames (B-mode ± color) with calipers for all measurements
    • Spectral Doppler waveforms (CCA, bulb, proximal ICA) with angle correction ≤60°

    Quality grading (apply your rules):

    • Grade 1 (excellent) / 2 (diagnostic) / 3 (limited) - use only Grades 1-2 in primary analysis; Grade 3 in sensitivity analysis.

    Reader guidance \& adjudication using your criteria:

    • Two blinded readers score Definite/Probable/Possible/Not CaW; discrepancies resolved by third reader under the same rubric.
    • 10% repeat reads for κ/ICC. CRF add-ons (pre-wired to your criteria)
    • Checkboxes for each criterion element (present/absent/not evaluable).
    • Auto-calculated category (Definite/Probable/Possible/Not CaW) based on boxes ticked.
    • Mandatory image IDs linked to each measurement. 8) Training, Blinding, and Adjudication
    • Sonographers undergo a standardized training module with exemplar images and checklists.
    • Blinding: Operators are blinded to participant clinical data except age/sex; central readers (two expert neurosonologists) are blinded to site and each other.
    • Adjudication: Disagreements (probable/possible/absent) resolved by a third senior reader.
    • Reliability: 10% random sample re-read for inter-observer agreement (Cohen's κ for categorical calls; ICC for continuous measures).

      9) Data Collection

    • Demographics: age, sex, ethnicity (optional), height/weight.
    • Vascular risk factors: smoking status, BP at visit, lipid profile if available, personal history of stroke/TIA/migraine, OCP use (females), recreational drugs, connective tissue disease/FMD history.
    • Ultrasound fields: laterality; CaW category (absent/possible/probable), web dimensions (length, thickness, projection angle-estimate), distance from flow divider, presence of superimposed thrombus, plaque descriptors, standard velocities (CCA, bulb, ICA), ICA/CCA PSV ratio, EDV.
    • Imaging quality scores and reasons for non-diagnostic studies.

      10) Validation Substudy

    • Participants with definite or possible CaW on DUS plus 1:2 matched DUS-negative controls (matched by age/sex/site) will be invited for CTA within 4 weeks to evaluate concordance (index test: DUS; reference standard: CTA with thin-slice oblique sagittal reconstructions). Outcome: sensitivity/specificity and positive predictive value of DUS criteria. (CTA descriptions of CaW as thin, shelf-like posterior bulb defects guide the reference call.)

      11) Statistical Analysis Plan

    • Weighting: Apply sampling weights for cluster/strata to estimate population prevalence; robust SEs (Taylor linearization) or survey-design GLMs.
    • Descriptives: Means/SDs or medians/IQRs; counts/% with 95% CIs.
    • Primary analysis: Weighted prevalence and exact (Clopper-Pearson) or Wilson CIs for rare events; compare strata with Rao-Scott χ².
    • Regression (exploratory): Survey-weighted Poisson (log link, robust variance) for prevalence ratios of CaW vs candidate covariates.
    • Reliability: Cohen's κ with 95% CI (categorical), ICC(2,1) for continuous measures.
    • Missing data: Report flow; use complete-case for primary prevalence; multiple imputation for covariate analyses if >5% missing.
    • Sensitivity analyses: (i) include possible CaW as positive; (ii) restrict to scans with top quality scores; (iii) per-reader estimates.

      13) Bias Minimization \& Quality Control

    • Pre-specified imaging protocol; machine presets harmonized across sites.
    • Central training and periodic recalibration; quarterly site audits of randomly selected studies.
    • Consecutive sampling within clusters to reduce selection bias; track response rates.
    • Maintain blinding; lock image sets before adjudication.

      14) Ethics and Safety

    • Minimal-risk imaging study; no ionizing radiation in the primary protocol.
    • Informed consent; separate consent for optional CTA.
    • Participants with incidental significant carotid stenosis or suspected thrombus receive counseling and referral per local care pathways.
    • Data privacy per GDPR; coded IDs; secure storage.
02

Conditions studied

  • Carotid Web

Keywords

  • Prevalence
  • Carotid artery
  • Carotid web
  • Duplex sonography
03

In context

Lead sponsor

University of Ostrava is the lead sponsor of 10 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

General population aged 15 - 25 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age 15 - 25 years at enrollment
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Prior carotid endarterectomy and/or angioplasty and stenting
  • Neck irradiation
  • Known vasculopathy with non-web lesions that preclude assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
829 participants (estimated)
Patient registry
No

Groups and cohorts

  • Youth

    Age 15 - 25 years

06

What researchers measure

Primary outcomes

  1. Prevalence

    Prevalence of web in youth population

    Time frame: on the day of the ultrasound examination

07

Study locations

1 of 1 sites recruiting
  • Faculty of Medicine, University of Ostrava
    Ostrava, Moravian-Silesian Region 70300, Czechia
    Recruiting
    • David Skoloudik, Prof., M.D., Ph.D · Contactskoloudik@email.cz · 00420739782970
    • David Pakizer, M.Sc., Ph.D. · Contactdavid.pakizer@email.cz · 00420776457295
    • Istvan Szegedi, M.D., Ph.D. · Sub investigator
    • David Skoloudik, Prof., M.D., Ph.D. · Principal investigator
08

References and documents

Publications

  • Yang J, Zhou F, Lei N, Liu R, Yang B, Zhang T, Li X, Xing Y. Carotid web ultrasonography and its associations with ischemic stroke: a preliminary observational study. BMC Neurol. 2025 Dec 3;26(1):18. doi: 10.1186/s12883-025-04486-w. PubMed 41340049 ↗
  • Talathi S, Lipsitz EC. Current Therapy for Carotid Webs. Ann Vasc Surg. 2025 Apr;113:415-420. doi: 10.1016/j.avsg.2024.08.014. Epub 2024 Oct 16. PubMed 39424178 ↗
  • Yang T, Yoshida K, Maki T, Fushimi Y, Yamada K, Okawa M, Yamamoto Y, Takayama N, Suzuki K, Miyamoto S. Prevalence and site of predilection of carotid webs focusing on symptomatic and asymptomatic Japanese patients. J Neurosurg. 2021 Mar 5;135(5):1370-1376. doi: 10.3171/2020.8.JNS201727. Print 2021 Nov 1. PubMed 33668027 ↗
  • Chen H, Colasurdo M, Costa M, Nossek E, Kan P. Carotid webs: a review of pathophysiology, diagnostic findings, and treatment options. J Neurointerv Surg. 2024 Nov 22;16(12):1294-1298. doi: 10.1136/jnis-2023-021243. PubMed 38290814 ↗
  • Fontaine L, Guidolin B, Viguier A, Gollion C, Barbieux M, Larrue V. Ultrasound characteristics of carotid web. J Neuroimaging. 2022 Sep;32(5):894-901. doi: 10.1111/jon.13022. Epub 2022 Jul 10. PubMed 35811446 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2026
First posted
Mar 27, 2026
StartActual
Jan 4, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 28, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07495241
Lead sponsor
University of Ostrava
Responsible party
Vendula Krcmarova (Professor of Neurology, University of Ostrava) — Principal investigator
First posted
Mar 27, 2026
Start date
Jan 4, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

David Školoudík, Prof., M.D., Ph.D.
Contact
skoloudik@email.cz
+420-739782970
David Pakizer, MSc., Ph.D.
Contact
david.pakizer@email.cz
+420-776457295
David Školoudík, Prof., M.D., Ph.D.
principal investigator · University of Ostrava

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion